secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0000950170-23-038312
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q2 core revenue rises 48% to $67M; raises FY2023 guidance to $260M
--------------------------------------------------------------------------------

- Total revenue $68M; core revenue $67M, up 48% YoY.
- GAAP net loss $11.2M ($0.38/share); Non-GAAP loss $2.4M ($0.08/share).
- Adjusted EBITDA loss $2.7M; cash flow from operations $9.7M.
- Raises full-year 2023 core revenue guidance to $260M, narrows expected loss.
- Cash, cash equivalents, and investments $846.8M as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/0000950170-23-038312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/flgt-20230804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer